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Abstract
Background: To clarify whether atherosclerosis of the carotid and intracranial arteries is related to Alzheimer’s
disease (AD) pathology in vivo, we investigated the associations of carotid and intracranial artery stenosis with
cerebral beta-amyloid (Aβ) deposition and neurodegeneration in middle- and old-aged individuals. Given different
variations of the pathologies between cognitive groups, we focused separately on cognitively normal (CN) and
cognitively impaired (CI) groups.
Methods: A total of 281 CN and 199 CI (mild cognitive impairment and AD dementia) subjects underwent
comprehensive clinical assessment, [11C] Pittsburgh compound B-positron emission tomography, and magnetic
resonance (MR) imaging including MR angiography. We evaluated extracranial carotid and intracranial arteries for
the overall presence, severity (i.e., number and degree of narrowing), and location of stenosis.
Results: We found no associations between carotid and intracranial artery stenosis and cerebral Aβ burden in
either the CN or the CI group. In terms of neurodegeneration, exploratory univariable analyses showed associations
between the presence and severity of stenosis and regional neurodegeneration biomarkers (i.e., reduced
hippocampal volume [HV] and cortical thickness in the AD-signature regions) in both the CN and CI groups. In
confirmatory multivariable analyses controlling for demographic covariates and diagnosis, the association between
number of stenotic intracranial arteries ≥ 2 and reduced HV in the CI group remained significant.
Conclusions: Neither carotid nor intracranial artery stenosis appears to be associated with brain Aβ burden, while
intracranial artery stenosis is related to amyloid-independent neurodegeneration, particularly hippocampal atrophy.
Keywords: Alzheimer’s disease, Amyloid beta, Neurodegeneration, Atherosclerosis, Intracranial stenosis, Carotid
stenosis, Cognitive impairment
Background
Clinical or epidemiological studies indicate the associ-
ation between atherosclerosis of the carotid and intra-
cranial arteries and Alzheimer’s disease (AD) dementia
[1–4]. However, the pathological links underlying the as-
sociation still remain unclear. Although some postmor-
tem studies reported the relationship between
atherosclerosis and amyloid plaques, a core pathology of
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AD [5–8], others did not find such relationship [4, 9–
11]. Regarding in vivo brain imaging approaches, a
couple of small-scale studies on individuals with severe
cerebral hypoperfusion yielded inconsistent findings on
the relationship between very severe atherosclerosis and
beta-amyloid (Aβ) deposition [12, 13]. A recent study
using high-resolution vessel wall magnetic resonance
(MR) imaging reported that intracranial atherosclerotic
plaque or stenosis was not associated with Aβ deposition
in nondemented adults [14]. Nevertheless, knowledge of
the association between carotid and intracranial athero-
sclerosis and other in vivo brain pathologies including
regional neurodegeneration, as well as Aβ deposition, in
the living human brain remains limited.
The relationships between carotid and intracranial ar-
tery atherosclerosis and in vivo brain pathologies may be
different according to the cognitive status of individuals
because of the following reasons: regional neurodegener-
ation is minimal in cognitively normal (CN) individuals,
resulting in floor effect, while it has wide variation in
those with cognitive impairment (CI), correlating with
the degree of cognitive decline [15]. In addition, many
AD dementia patients show almost saturated Aβ depos-
ition, possibly resulting in ceiling effect [15]. Given these
reasons, a cognitive state-specific approach, separately
focusing on CN and CI individuals, could be helpful.
We aimed to investigate the associations between ca-
rotid and intracranial artery stenosis systematically mea-
sured on MR angiography and AD biomarkers including
cerebral Aβ deposition and regional neurodegeneration




This study is part of the Korean Brain Aging Study for
Early Diagnosis and Prediction of Alzheimer’s Disease
(KBASE), an ongoing prospective, community-based co-
hort study [16]. As of February 2017, a total of 480 older
adults consisting of 281 CN and 199 CI (MCI and AD
dementia) subjects were initially recruited. The inclusion
criteria for the CN group were (a) aged 55–90 years, (b)
no diagnosis of MCI or dementia, and (c) Clinical De-
mentia Rating (CDR) score of 0. For the MCI group, in-
dividuals 55–90 years old who fulfilled the core clinical
criteria for diagnosis of MCI according to the recom-
mendations of the National Institute on Aging-
Alzheimer’s Association (NIA-AA) guidelines [17] were
included as follows: (a) memory complaints corroborated
by the patient, an informant, or clinician; (b) objective
memory impairment for age, education, and gender (i.e.,
at least 1.0 SD below the respective age, education, and
gender-specific mean for at least one of the four episodic
memory tests included in the Korean version of
Consortium to Establish a Registry for Alzheimer’s Dis-
ease (CERAD-K) neuropsychological battery [Word List
Memory, Word List Recall, Word List Recognition, and
Constructional Recall test]); (c) largely intact functional
activities; and (d) no dementia. The global CDR score of
all MCI individuals was 0.5. For the AD dementia group,
participants 55–90 years old who fulfilled the following
inclusion criteria were recruited: (a) criteria for dementia
in accordance with the Diagnostic and Statistical Manual
of Mental Disorders 4th Edition (DSM-IV-TR), (b) the
criteria for probable AD dementia in accordance with
the NIA-AA guidelines [18], and (c) a global CDR score
of 0·5 or 1. For all groups, individuals with the following
conditions were excluded from the study: (1) presence of
major psychiatric illness; (2) significant neurological or
medical condition or comorbidities that could affect
mental function; (3) contraindications to MRI (e.g., pace-
maker, claustrophobia); (4) illiteracy; (5) presence of sig-
nificant visual/hearing difficulty, and severe
communication or behavioral problems that would make
clinical examination or brain scan difficult; (6) taking an
investigational drug; and (7) pregnant or breastfeeding.
More detailed information on recruitment of the KBASE
cohort was described in our previous report [16]. This
study protocol was approved by the Institutional Review
Boards of Seoul National University Hospital and SNU-
SMG Boramae Medical Center, Seoul, South Korea. The
participants and/or their legal representatives provided
written informed consent.
Clinical assessment
All participants were administered comprehensive clin-
ical and neuropsychological assessments by trained psy-
chiatrists and neuropsychologists based on the KBASE
assessment protocol which incorporates the CERAD-K
[16]. Blood samples were collected to determine apolipo-
protein E ε4 allele (APOE4) carrier status. Vascular risk
factors, including hypertension, diabetes mellitus, hyper-
lipidemia, coronary artery disease, transient ischemic at-
tack, and stroke, were evaluated via systematic interview
by trained nurses, and vascular risk score was calculated
for the number of vascular risk factors present and re-
ported as a percentage [16].
Image acquisition, preprocessing, and measurement of
vessel stenosis and AD biomarkers
All subjects underwent simultaneous three-dimensional
(3D) [11C] Pittsburgh compound B (PiB)-positron emis-
sion tomography (PET), 3D T1-weighted MRI, fluid-
attenuated inversion (FLAIR) images, and 3D time-of-
flight (TOF)-MR angiography using the 3.0-T Biograph
mMR (PET-MR) scanner (Siemens, Washington DC,
USA). Acquisition parameters for MRI and MR angiog-
raphy are described in Methods S1 (Additional file 1).
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Systematic evaluation of stenosis on MR angiography
Diagnosis of extracranial carotid and intracranial arterial
stenosis was reached by the consensus between two
qualified neuroradiologists (KMK and CHS) blinded to
the participants’ clinical information. We recorded the
overall presence, the number, and the degree of detect-
able stenotic lesions in the following 13 arterial seg-
ments: right and left proximal cervical internal carotid
artery (ICA); right and left intracranial ICA; right and
left anterior, middle, and posterior cerebral arteries; right
and left intracranial vertebral artery; and basilar artery.
For the extracranial carotid artery, the degree of stenosis
was measured according to the North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET) cri-
teria [19] using maximum-intensity projections and
source images of the bifurcation of the carotid artery. In
cases of intracranial arterial stenosis, the degree of sten-
osis was calculated based on maximum-intensity projec-
tions and source images using the method published for
the Warfarin-Aspirin Symptomatic Intracranial Disease
Study [20]: percent stenosis = [(1 − (Dstenosis/Dnormal)] ×
100. In the case of an artery with multiple stenotic le-
sions, the most severe degree was selected. Based on the
above quantitative data, participants were categorized
into stenosis-positive (stenosis+) vs. stenosis-negative
(stenosis−) groups according to the stenosis measure-
ments for extracranial carotid and intracranial arteries as
follows: (i) overall presence of any detectable stenosis
and (ii) severity (i.e., the degree of stenosis ≥ 50%, and
number of stenotic arteries ≥ 2). In terms of the location
of intracranial arterial stenosis, the presence of detect-
able stenosis in the anterior circulation and posterior
circulations was also evaluated. Anterior circulation
stenosis was defined as any detectable stenosis in ICA
and anterior or middle cerebral arteries. Posterior circu-
lation stenosis included any detectable stenosis in intra-
cranial vertebral or basilar arteries. As there were only
very limited numbers of cases with ≥ 50% stenotic le-
sions in the extracranial carotid arteries (1 of 281 sub-
jects in the CN group and 1 of 196 subjects in the CI
group), and those with bilateral extracranial carotid sten-
osis (6 of 281 subjects in the CN group and 6 of 196
subjects in the CI group) in our sample, these measure-
ments could not be applied to the extracranial carotid
arteries and only available for evaluation of intracranial
arterial stenosis.
Beta-amyloid (Aβ) biomarker
For measurement of Aβ biomarker of AD, a 30-min
emission scan was obtained 40min after injection of
intravenous administration of 555MBq of [11C] PiB
(range, 450–610MBq). The [11C] PiB-PET data collected
in list mode were processed for routine corrections such
as uniformity, UTE-based attenuation, and decay
corrections, and were reconstructed into a 344 × 344
image matrix using iterative methods (5 iterations with
21 subsets). The image preprocessing steps were per-
formed using Statistical Parametric Mapping 8 (SPM8;
http://www.fil.ion.ucl.ac.uk/spm) implemented in MATL
AB 2014a (MathWorks, Natick, MA, USA). Static [11C]
PiB-PET images were coregistered to individual T1
structural images, and transformation parameters for
spatial normalization of individual T1 images to a stand-
ard Montreal Neurological Institute (MNI) template
were calculated. The inverse transformation of parame-
ters to transform coordinates from the automatic ana-
tomic labeling (AAL) 116 atlas [21] into an individual
space for each subject (resampling voxel size = 1 × 0.98 ×
0.98 mm) was performed using IBASPM (Individual
Brain Atlases using Statistical Parametric Mapping) soft-
ware in MATLAB. To extract gray matter (GM) and ex-
clude the non-GM portions of the atlas (i.e., white
matter [WM] and cerebrospinal fluid space), a GM
mask, which is a binary probabilistic GM map generated
by preprocessing step using SPM8, was applied for each
individual. The mean regional [11C] PiB uptake values
from cerebral regions were extracted using the individ-
ual AAL 116 atlas from T1-coregistered [11C] PiB-PET
images. Cerebellar GM was used as the reference region
for quantitative normalization of cerebral [11C] PiB up-
take values, due to its relatively low Aβ deposition [22],
with a probabilistic cerebellar atlas (Institute of Cogni-
tive Neuroscience, UCL; Cognitive Neuroscience La-
boratory, Royal Holloway, University of London, UK)
which was transformed into individual space as de-
scribed above. The AAL algorithm and a region combin-
ing method [23] were applied to determine regions of
interest (ROIs) to characterize the [11C] PiB retention
levels in the frontal, lateral parietal, posterior cingulate-
precuneus, and lateral temporal regions. A global Aβ re-
tention value (standardized uptake value ratio, SUVR)
was generated by dividing the voxel-weighted mean
value of the four ROIs by the mean cerebellar uptake
value [23–25]. Aβ positivity was defined if [11C] PiB
SUVR value was > 1.4 in at least one of the abovemen-
tioned four ROIs [23–25].
Neurodegeneration biomarker
All T1-weighted MR images were automatically seg-
mented using FreeSurfer version 5.3 (http://surfer.nmr.
mgh.harvard.edu/) with manual correction of minor seg-
mentation errors. As AD-related neurodegeneration bio-
markers, both AD-signature cortical thickness (AD-CT;
i.e., mean cortical thickness obtained from AD-signature
regions) and hippocampal volume adjusted for intracra-
nial volume (HVa) were measured as described previ-
ously [24]. First, AD-CT was defined as the mean
cortical thickness values of AD-signature regions
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including the entorhinal, inferior temporal, middle tem-
poral, and fusiform gyrus, based on the Desikan–Killiany
atlas [26]. Second, to obtain HVa, left and right hippo-
campi volume from the FreeSurfer extracted output
were first added together to yield the total hippocampal
volume (HV). Then, the volume deviating from the ex-
pected total HV according to intracranial volume (ICV)
based on the reference group (i.e., young CN group of
the study cohort [KBASE]), which was not included in
the present study, was calculated to obtain HVa as de-
scribed in the previous study [24, 27]. Briefly, a linear re-
gression line was derived based on the young control
group (i.e., the reference group) using their ICV and
total HV. HVa, then, is the residual from the linear re-
gression of HV (y-axis) vs. ICV (x-axis); therefore, the
HVa is interpreted as the amount of deviation in a sub-
ject’s hippocampal volume from what is expected given
their ICV.
White matter hyperintensities
The volume of white matter hyperintensities (WMH) on
FLAIR images was calculated using a validated auto-
matic procedure [28] with two modifications, as follows:
First, an optimal threshold of 70 instead of 65 in the ori-
ginal reference was applied, as the original study [28]
recommended adjustment of the threshold for each
study dataset to capture the voxels with WMH better
than 65 without including non-WMH voxels. More de-
tailed information on the adjustment of the threshold is
described in Methods S2 (Additional file 1). Second,
diffusion-weighted imaging was not used in the present
automated procedure as there were no participants with
acute cerebral infarcts in our study population. WMH
candidate images were used to extract WMH volumes
based on lobar ROIs in the native space for each subject
[29].
Statistical analysis
Clinical characteristics were compared between CN and
CI, and between MCI and AD dementia using the chi-
square and Fisher exact tests to compare data distribu-
tions, and independent t test to compare means of con-
tinuous variables. Interobserver agreement for stenosis
was determined by calculating Cohen’s kappa correlation
coefficient from 125 randomly selected individuals.
The association between a measure of extracranial ca-
rotid or intracranial stenosis and AD biomarkers (i.e.,
global Aβ deposition, AD-CT, and HVa) was investi-
gated focusing on CN and CI separately, with two steps
of analysis including exploratory and confirmative steps.
Exploratory univariable analyses were performed with
independent t test to compare the quantitative values of
AD biomarkers between the stenosis+ and stenosis−
groups. Cohen’s d was determined to imply the effect
size of the discrepancy between sequences. The AD bio-
markers with p < 0.05 in exploratory univariable analyses
were selected for the next confirmatory multivariable
analyses. Confirmative multivariable analyses using gen-
eral linear model (GLM) were conducted for the selected
biomarker adjusting for age, sex, and APOE4 carrier sta-
tus for the CN group, and for age, sex APOE4 carrier
status, and clinical diagnosis (MCI or AD dementia) for
the CI group. The Bonferroni correction method was ap-
plied to multiple comparisons using p < 0.05/no. of con-
firmatory analyses within each cognitive group. The
same analyses with WMH volume as an additional co-
variate were also conducted to evaluate the mediating ef-
fect of WM lesions.
All statistical analyses except calculating Cohen’s d
were performed using IBM SPSS Statistics 23 (SPSS Inc.,
Chicago, IL, USA), and p < 0.05 (two-sided) was taken to
indicate statistical significance unless otherwise specified.
Cohen’s d was calculated using effsize package in the R
4.0.0.
Results
Characteristics of the participants
The demographic and clinical characteristics of the par-
ticipants are presented in Table 1. Data on the presence
of vessel stenosis and AD biomarkers of the participants
are also shown in Table 2. Three cases were excluded
from the evaluation of extracranial carotid stenosis due
to motion artifacts. The characteristics of MCI and AD
dementia subgroups in the CI group are also presented
Table 1 Demographic and clinical characteristics of participants
Variables CN (N = 281) CI (N = 199) p value
Age, years 69.1 ± 8.1 72.9 ± 7.4 < 0.001*
Females 146 (52.0%) 134 (67.3%) 0.001*
Education, years 11.9 ± 4.8 9.7 ± 4.9 < 0.001*
APOE4 carriers 52 (18.5%) 83 (41.7%) < 0.001*
Global CDR (0/0.5/1) 281/0/0 0/153/46 < 0.001*
CDR-SOB 0.0 ± 0.1 2.7 ± 2.0 < 0.001*
Hypertension 133 (47.3%) 99 (49.7%) 0.602
Diabetes mellitus 46 (16.4%) 34 (17.1%) 0.836
Coronary artery disease 16 (5.7%) 10 (5.0%) 0.470
Hyperlipidemia 96 (34.2%) 71 (35.7%) 0.731
Stroke 0 (0.0%) 0 (0.0%) NA
Transient ischemic attack 2 (0.7%) 1 (0.5%) 0.774
Vascular risk factor score 17.4 ± 16.11 18.0 ± 16.8 0.679
WMH volume (cm3)a 5.7 ± 5.3 6.4 ± 5.2 0.202
Data are presented as mean ± SD or n (%)
CN cognitively normal, CI cognitively impaired, MCI mild cognitive impairment,
AD dementia, Alzheimer’s dementia, CDR-SOB Clinical Dementia Rating sum of
box, WMH white matter hyperintensities
aData for 422 individuals were available (256 CN and 166 CI)
*p < 0.05
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in Table S1 and S2 in Additional file 2. The CI group
Table 2 Vessel stenosis features and AD biomarkers of participants
Variables CN (N = 281) CI (N = 199) p value
Large vessel stenosis
Presence of any detectable stenosis
Any extracranial carotid stenosis 23 (8.2%) 22 (11.2%)a 0.264
Any intracranial stenosis 77 (27.4%) 71 (35.7%) 0.053
Both extracranial carotid and intracranial stenosis 12 (4.3%) 10 (5.0%) 0.697
Presence of stenosis based on severity threshold
≥ 50% intracranial stenosis 19 (6.8%) 21 (10.6%) 0.139
Number of stenotic intracranial arteries ≥ 2 44 (15.7%) 38 (19.1%) 0.324
Presence of stenosis according to location
Anterior circulation stenosis 69 (24.6%) 61 (30.7%) 0.139
Posterior circulation stenosis 21 (7.5%) 21 (10.6%) 0.239
AD biomarkers
Global Aβ deposition (SUVR) 1.184 ± 0.239 1.621 ± 0.156 < 0.001*
Aβ positivity 39 (13.9%) 112 (56.3%) < 0.001*
Neurodegeneration biomarkers
AD-CT (mm) 2.866 ± 0.174 2.584 ± 0.286 < 0.001*
HVa (mm3) − 759 ± 838 − 2132 ± 1219 < 0.001*
Data are presented as mean ± SD or n (%)
CN cognitively normal, CI cognitively impaired, AD-CT Alzheimer’s disease-signature cortical thickness, HVa hippocampal volume adjusted for intracranial volume
aAmong CI group, data for 196 individuals were available
*p < 0.05
Table 3 Exploratory univariable analyses for the association between extracranial carotid and intracranial arterial stenosis and AD
biomarkers in the CN group
AD biomarker Variables Presence of any detectable stenosis
Any extracranial carotid stenosis Any intracranial stenosis
Stenosis− Stenosis+ p value da Stenosis− Stenosis+ p value d
Aβ biomarker Global Aβ 1.185 ± 0.245 1.173 ± 0.160 0.810 0.052 1.182 ± 0.243 1.190 ± 0.230 0.782 − 0.037
Neurodegeneration biomarker AD-CT 2.877 ± 0.170 2.743 ± 0.173 < 0.001* 0.786 2.890 ± 0.171 2.804 ± 0.165 < 0.001* 0.505
HVa − 732 ± 810 − 1067 ± 1076 0.066 0.401 − 686 ± 832 − 953 ± 0827 0.017* 0.322
Presence of stenosis based on severity threshold
≥ 50% intracranial stenosisb Number of stenotic intracranial arteries ≥ 2c
Stenosis− Stenosis+ p value d Stenosis− Stenosis+ p value d
Aβ biomarker Global Aβ 1.179 ± 0.234 1.258 ± 0.293 0.165 − 0.331 1.189 ± 0.242 1.157 ± 0.221 0.409 0.136
Neurodegeneration biomarker AD-CT 2.871 ± 0.175 2.801 ± 0.136 0.091 0.403 2.882 ± 0.169 2.780 ± 0.178 < 0.001* 0.603
HVa − 746 ± 838 − 937 ± 837 0.338 0.228 − 726 ± 840 − 938 ± 810 0.123 0.254
Presence of stenosis according to location
Anterior circulation Posterior circulation
Stenosis− Stenosis+ p value d Stenosis− Stenosis+ p value d
Aβ biomarker Global Aβ 1.187 ± 0.245 1.175 ± 0.220 0.711 0.052 1.185 ± 0.241 1.175 ± 0.212 0.854 0.042
Neurodegeneration biomarker AD-CT 2.884 ± 0.172 2.811 ± 0.167 0.002* 0.428 2.876 ± 0.170 2.744 ± 0.181 0.001* 0.772
HVa − 710 ± 837 − 911 ± 828 0.082 0.242 − 760 ± 836 − 746 ± 875 0.943 − 0.016
Data for continuous variables presented as means ± SD (SUVR for global Aβ, mm for AD-CT, and mm3 for HVa)
CN cognitively normal, SUVR standardized uptake value ratio, AD-CT Alzheimer’s disease-signature cortical thickness, HVa hippocampal volume adjusted for
intracranial volume
ad indicates Cohen’s delta
b“Stenosis−” group of “≥ 50% intracranial stenosis” means individuals with no stenosis or < 50% intracranial stenosis
c“Stenosis−” group of “number of stenotic intracranial arteries ≥ 2” means patients with no stenosis or only one stenotic intracranial artery
*p < 0.05
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consisted of 129 subjects with MCI and 70 subjects with
AD dementia.
Reproducibility of a measure of extracranial carotid or
intracranial stenosis
The results of the interobserver agreement for a measure
of extracranial carotid or intracranial stenosis are shown
as Table S3 in Additional file 2. The kappa values were
0.715 for extracranial carotid stenosis, 0.869 for any
intracranial stenosis, 0.715 for number of stenotic intra-
cranial arteries ≥ 2, 0.802 for anterior circulation sten-
osis, and 1 for posterior circulation stenosis. The kappa
value for ≥ 50% stenosis was 0.301 due to the very low
prevalence of ≥ 50% stenosis despite the high degree of
interobserver agreement.
Association of carotid and intracranial stenosis with AD
biomarkers in the CN group
In the exploratory step of the analyses, we found no sig-
nificant differences in global Aβ deposition between CN
subjects with vs. those without any type of stenosis
(Table 3). In contrast, with regard to neurodegeneration
biomarkers, AD-CT was significantly reduced in CN
subjects in the stenosis+ group compared with CN sub-
jects in the stenosis− group for the presence of any ex-
tracranial carotid stenosis, presence of any intracranial
stenosis, number of stenotic intracranial arteries ≥ 2, an-
terior circulation stenosis, and posterior circulation sten-
osis (all p < 0.05; Table 3). In addition, HVa was
significantly reduced in the stenosis+ CN group com-
pared to the stenosis− CN group for the presence of any
intracranial arterial stenosis. Next, for confirmatory ana-
lyses in the CN group, we further investigated the asso-
ciations between AD-CT and each of the
abovementioned five measurements of stenosis that
showed association in exploratory univariable analyses
(p < 0.05), as well as the association between HVa and
presence of any intracranial stenosis, after controlling
for the effects of age, sex, and APOE4 carrier status
(Table 4). When Bonferroni-corrected p value (p < 0.05/
6 = 0.008) was applied, these associations were not sig-
nificant in the confirmatory analyses, although posterior
circulation stenosis showed a trend for association with
reduced AD-CT (p = 0.030).
Association of carotid and intracranial stenosis with AD
biomarkers in the CI group
In the CI group, exploratory univariable analyses found
an association between anterior circulation stenosis and
lower global Aβ deposition (p = 0.049, Table 5). How-
ever, it was not significant in the confirmatory step when
controlling for age, gender, APOE4 carrier status, and
clinical diagnosis (MCI vs. AD dementia) (B = − 0.096,
SE = 0.072, and p = 0.183). In terms of exploratory uni-
variable analyses of neurodegeneration biomarkers, there
were no differences in AD-CT between the stenosis+
and stenosis− groups for any type of stenosis in CI sub-
jects (Table 5). However, the presence of any intracranial
arterial stenosis and number of stenotic intracranial ar-
teries ≥ 2 were associated with reduced HVa in CI sub-
jects (p = 0.047 and p = 0.008, respectively; Table 5).
These two associations were selected for subsequent
confirmatory multivariable analyses after controlling for
age, gender, APOE4 carrier status, and clinical diagnosis
(Table 6). Bonferroni-corrected p < 0.05/2 = 0.025 was
used as a statistical threshold. In the confirmatory multi-
variable analyses, CI subjects with number of stenotic
intracranial arteries ≥ 2 had significantly lower HVa than
those without when controlling for age, gender, APOE4
carrier status, and clinical diagnosis (p = 0.021; Figs. 1
and 2). The results did not change even after additional
adjustment for WMH volume (B = − 509.45, SE = 205.55,
and p = 0.014). In order to investigate whether the pres-
ence of Aβ deposition (i.e., Aβ positivity) moderates the
association between the stenosis and lower HVa, we
additionally tested similar GLM model including the
Table 4 Confirmatory multivariable analyses for the association between extracranial carotid and intracranial arterial stenosis and
neurodegeneration biomarkers in the CN group
AD biomarker Variables Type of stenosis B SE p
Neurodegeneration biomarker AD-CT Any extracranial carotid stenosis − 0.051 0.033 0.121
Any intracranial stenosis − 0.033 0.020 0.104
Number of stenotic intracranial arteries ≥ 2 − 0.040 0.025 0.113
Anterior circulation − 0.024 0.021 0.254
Posterior circulation − 0.074 0.034 0.030*
HVa Any intracranial stenosis − 30.760 95.491 0.748
Covariates for confirmatory multivariable analyses include age, sex, and APOE4 carrier status. Units for AD biomarker variables are as follows: SUVR for global Aβ,
mm for AD-CT, and mm3 for HVa. When Bonferroni-corrected p value (p < 0.05/6 = 0.008) was applied for confirmatory multivariable analyses regarding
neurodegeneration biomarkers, these associations were not significant, although posterior circulation stenosis showed a trend for association with reduced AD-CT
AD Alzheimer’s disease, CN cognitively normal, SE standard error, AD-CT Alzheimer’s disease-signature cortical thickness, HVa hippocampal volume adjusted for
intracranial volume
aNo significant findings in the exploratory univariable analyses step regarding Aβ biomarker
*p < 0.05 (before Bonferroni correction)
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stenosis (i.e., number of stenotic intracranial arteries ≥
2) × Aβ positivity interaction term, as well as the stenosis
itself, as an independent variable. In this analysis, we did
not find any significant stenosis × Aβ positivity inter-
action effect. On the other hand, the association between
presence of any intracranial stenosis and lower HVa in
the CI group did not remain significant in confirmatory
analysis (p = 0.597; Table 6).
Discussion
This study was performed to investigate the associations
of both extracranial carotid and intracranial artery sten-
osis with in vivo AD pathologies, i.e., global Aβ burden
and neurodegeneration in a large number of older
adults, focusing on the CN and CI groups separately.
Global Aβ burden was not related to any vessel stenosis
in either group. With regard to neurodegeneration, the
CN group did not show any significant associations be-
tween carotid and intracranial artery stenosis and AD-
CT or HVa. In contrast, in the CI group, number of
stenotic intracranial arteries ≥ 2 was significantly associ-
ated with lower HVa even after adjusting for age, gender,
APOE4 carrier status, and diagnosis (i.e., MCI vs. AD
dementia).
A number of previous postmortem brain studies inves-
tigated the association between cerebral atherosclerosis
and Aβ burden, but the results were controversial [1–8].
While a number of previous autopsy studies reported a
Table 5 Exploratory univariable analyses for the association between extracranial carotid and intracranial arterial stenosis and AD
biomarkers in the CI group
AD biomarker Variables Presence of any detectable stenosis
Any extracranial carotid stenosis Any intracranial stenosis
Stenosis− Stenosis+ p value da Stenosis− Stenosis+ p value d
Aβ biomarker Global Aβ 1.627 ± 0.530 1.609 ± 0.412 0.857 0.334 1.648 ± 0.539 1.573 ± 0.472 0.304 0.147
Neurodegeneration biomarker AD-CT 2.600 ± 0.284 2.518 ± 0.260 0.205 0.288 2.596 ± 0.311 2.561 ± 0.234 0.376 0.121
HVa − 2064 ± 1225 − 2396 ± 947 0.146 0.277 − 2004 ± 1262 − 2362 ± 1109 0.047* 0.296
Presence of stenosis based on severity threshold
≥ 50% intracranial stenosisb Number of stenotic intracranial arteries ≥ 2c
Stenosis− Stenosis+ p value d Stenosis− Stenosis+ p value d
Aβ biomarker Global Aβ 1.646 ± 0.522 1.415 ± 0.411 0.052 0.451 1.640 ± 0.536 1.544 ± 0.414 0.234 0.185
Neurodegeneration biomarker AD-CT 2.584 ± 0.290 2.579 ± 0.254 0.940 0.017 2.598 ± 0.292 2.521 ± 0.252 0.136 0.270
HVa − 2087 ± 1202 − 2515 ± 1327 0.128 0.352 − 2021 ± 1227 − 2602 ± 1080 0.008* 0.484
Presence of stenosis according to location
Anterior circulation Posterior circulation
Stenosis− Stenosis+ p value d Stenosis− Stenosis+ p value d
Aβ biomarker Global Aβ 1.667 ± 0.535 1.519 ± 0.456 0.049* 0.288 1.623 ± 0.519 1.605 ± 0.498 0.878 0.035
Neurodegeneration biomarker AD-CT 2.585 ± 0.309 2.580 ± 0.224 0.902 0.017 2.589 ± 0.289 2.540 ± 0.257 0.459 0.171
HVa − 2047 ± 1244 − 2323 ± 1147 0.142 0.227 − 2100 ± 1217 − 2400 ± 1236 0.287 0.246
Data for continuous variables presented as means ± SD (SUVR for global Aβ, mm for AD-CT, and mm3 for HVa)
CI cognitively impaired, SUVR standardized uptake value ratio, AD-CT Alzheimer’s disease-signature cortical thickness, HVa hippocampal volume adjusted for
intracranial volume
ad indicates Cohen’s delta
b“Stenosis−” group of “≥50% intracranial stenosis” means individuals with no stenosis or < 50% intracranial stenosis
c“Stenosis−” group of “number of stenotic intracranial arteries ≥ 2” means patients with no stenosis or only one stenotic intracranial artery
*p < 0.05
Table 6 Confirmatory multivariable analyses for the association between extracranial carotid and intracranial arterial stenosis and
HVa in the CI group
AD biomarker Variables Type of stenosis B SE p
Neurodegeneration biomarker HVa Any intracranial stenosis − 84.119 158.679 0.597
Number of stenotic intracranial arteries ≥ 2 − 428.816 184.921 0.021*†
Covariates for confirmatory multivariable analyses include age, sex, APOE4 carrier status, and clinical diagnosis (mild cognitive impairment or AD dementia). Units
for AD biomarker variables are as follows: SUVR for global Aβ, mm for AD-CT, and mm3 for HVa. When Bonferroni-corrected p value was applied for confirmatory
multivariable analyses regarding neurodegeneration biomarkers, the association between presence of number of stenotic intracranial arteries ≥ 2 and lower HVa
in the CI group remained significant
AD Alzheimer’s disease, CI cognitively impaired, SE standard error, SUVR standardized uptake value ratio, HVa hippocampal volume adjusted for
intracranial volume
aNo significant findings in the exploratory univariable analyses step regarding Aβ biomarker and AD-CT
*p < 0.05 (before Bonferroni correction)
†p < 0.025 (Bonferroni-corrected p < 0.05/2 = 0.025 was used as a statistical threshold)
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significant association between intracranial atheroscler-
osis and neuritic plaques in AD [1–4], several others
found no such associations [5–8]. Recently, a
community-based study in adults without dementia re-
ported that intracranial atherosclerotic plaque or sten-
osis was not associated with Aβ deposition in the brain
[14]. Our results in the CN and CI groups are in agree-
ment with the study [14] regarding the relationship be-
tween carotid and intracranial stenosis and global Aβ
burden. As both cerebral atherosclerosis and Aβ depos-
ition are common in the elderly, the possibility of coinci-
dence cannot be excluded in postmortem studies with
positive association between the two.
In contrast to global Aβ burden, intracranial artery
stenosis was associated with neurodegeneration bio-
markers in the CI group. In particular, number of sten-
otic intracranial arteries ≥ 2 was significantly associated
with lower hippocampal volume in CI subjects in con-
firmatory multivariable analysis. Some previous studies
identified intracranial atherosclerosis as an independent
risk factor for cerebral atrophy [5, 30]. In these studies,
however, intracranial atherosclerosis was assessed based
only on cavernous ICA calcification on computed tom-
ography [30] or pathological examination of the circle of
Willis [31]. In contrast, we evaluated stenosis of all cere-
bral arteries. With this approach and strict control for
multiple testing errors, we confirmed the association be-
tween intracranial artery stenosis and HVa in the CI
group. The association remained significant even after
controlling for WMH volume, suggesting that
intracranial artery stenosis affects hippocampal atrophy
independently of changes in the WM. Hippocampal at-
rophy is a validated neurodegeneration biomarker of AD
and is closely correlated with early cognitive decline
in AD [32]. Therefore, the association of intracranial
stenosis with decreased HVa, together with no associ-
ation with Aβ burden, in the CI group indicates that
intracranial stenosis contributes to the development
of CI via Aβ-independent neurodegeneration of the
hippocampus.
In the CN group, while exploratory univariable ana-
lyses showed relations between various types of sten-
osis and AD-CT or HVa in CN, such relations were
not confirmed by multivariable analyses with a strict
statistical threshold. Nevertheless, AD-CT tended to
be lower in subjects with posterior circulation stenosis
than those without (p = 0.03), although the difference
was not statistically significant after Bonferroni cor-
rection. In a previous postmortem study which re-
ported the association between intracranial artery
atherosclerosis and AD dementia, the posterior cere-
bral artery (PCA), one of the posterior circulation,
showed the most severe atherosclerosis among the
circle of Willis arteries in AD dementia patients [7].
Therefore, the potential association between posterior
circulation stenosis and AD-CT deserves attention.
Actually, the AD-signature regions, where we mea-
sured cortical thickness, include the entorhinal, infer-
ior temporal, and fusiform gyri that receive blood
supply from the PCA.
Fig. 1 Comparison of HVa between the stenosis− and stenosis+ groups for number of stenotic intracranial arteries ≥ 2 in CI subjects. In the box-
and-whisker plot, the central box represents the values from the lower to upper quartile, the middle line represents the median, and the
horizontal line extends from the minimum to the maximum value. *Adjusted p < 0.05 (after controlling for the effects of age, gender, APOE4, and
clinical diagnosis (MCI vs. AD dementia)). HVa, hippocampal volume adjusted for intracranial volume; MCI, mild cognitive impairment; AD,
Alzheimer’s disease
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We found no significant associations between extra-
cranial carotid stenosis and AD biomarkers regardless of
the presence of cognitive impairment. Some previous
in vivo studies with very small sample sizes investigated
the associations between severe carotid stenosis or oc-
clusion and Aβ deposition and yielded contradictory
findings. While one study using [18F] AV-45 PET indi-
cated that Aβ deposition increased in dementia patients
with unilateral carotid artery stenosis, and its distribu-
tion was lateralized to the side of stenosis [12], a more
recent study using [18F] flutemetamol PET indicated that
cerebral hypoperfusion caused by unilateral occlusion of
the ICA did not induce brain accumulation of Aβ [13].
In terms of neurodegeneration, our results were incon-
sistent with several previous studies that showed in-
creased carotid intima–media thickness and carotid
stenosis were associated with decreased total brain vol-
ume [8, 33]. This discrepancy may have been due to the
severity of stenosis. Only a very small number of sub-
jects with ≥ 50% stenosis in the extracranial carotid ar-
tery were included in the present study (1 of 281
subjects in the CN group and 1 of 196 subjects in the CI
group), while many previous studies indicated associa-
tions of the degree of severity [3, 33] or severe carotid
atherosclerosis [34, 35] with brain atrophy.
To our knowledge, this is the first study to investigate
the association between MR angiography-measured ves-
sel stenosis in the extracranial carotid and intracranial
arteries and in vivo AD pathologies, including both Aβ
deposition and neurodegeneration, in a large sample of
older adults, focusing separately on the CN and CI
groups. However, there were some limitations in our
study. First, due to its cross-sectional design, we cannot
make conclusions regarding the cause and effect rela-
tionship between carotid and intracranial artery stenosis
and in vivo AD pathologies. Second, although we in-
cluded a relatively large number of subjects, the frequen-
cies of stenosis, particularly extracranial carotid stenosis,
number of stenotic intracranial arteries ≥ 2, and poster-
ior circulation stenosis, were relatively low in both the
CN and CI groups, which may have reduced statistical
power and made it difficult to identify significant
Fig. 2 Representative MR angiographic images of intracranial and neck vessels, and coronal sections of T1-weighted images showing medial
temporal structures including the bilateral hippocampi of CI individuals in the a stenosis− group and b stenosis+ group with regard to number
of stenotic intracranial arteries ≥ 2. a Stenosis−: MR angiography of a 77-year-old woman with MCI with no steno-occlusive lesions in both
intracranial and neck vessels. HVa was − 1052mm3, and no significant hippocampal atrophy was observed in coronal sections on T1-weighted
MRI. b Stenosis+: MR angiography of an 81-year-old woman with MCI with multifocal intracranial arterial stenosis, while no steno-occlusive
lesions were found in the extracranial carotid arteries. HVa was − 3862mm3, and coronal sections on T1-weighted MRI indicate bilateral
hippocampal atrophy. MR, magnetic resonance; HVa, hippocampal volume adjusted for intracranial volume; MCI, mild cognitive impairment
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associations after multiple comparison correction. Ca-
rotid and intracranial artery stenosis has not been a
common finding in community-dwelling subjects [36,
37], with reported prevalence rates of asymptomatic
intracranial stenosis ranging from 5.9 to 24.5% [37]. In
addition, the prevalence of cervical carotid artery sten-
osis varies significantly with ethnicity, and it was re-
ported to be particularly uncommon in a Korean
population-based screening cohort [36]. Therefore, our
study population seemed to reflect the prevalence of
asymptomatic carotid and intracranial stenosis in the
general Asian population. Finally, given that about 55%
of MCI individuals and 23% of clinically defined AD de-
mentia patients among the subjects were Aβ negative,
brain pathological conditions other than AD and vascu-
lar lesions, such as primary age-related taupathy, hippo-
campal sclerosis, and argyrophilic grain disease, might
contribute to neurodegenerative changes. Future studies
including the examination of the conditions are needed.
Conclusions
In conclusion, our findings suggested that neither ca-
rotid nor intracranial artery stenosis is associated with
brain Aβ burden, while intracranial artery stenosis is re-
lated to amyloid-independent neurodegeneration, par-
ticularly hippocampal atrophy.
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